VICAM, a leading provider of mycotoxin testing solutions, is relocating its operations from Watertown, Massachusetts, to the headquarters facility of its parent company, Waters Corporation of Milford, Massachusetts. The move follows the acquisition of VICAM by Waters.
The move to a new state-of-the-art facility is expected to be completed by May 29, 2009. VICAM is assuring a seamless transition of services and support for its customers and international distributors who can access order via mail for phone.
"Our move is great news for VICAM, as well as for our customers and specialized distributors," aid Marjorie Radlo general manager, director of Operations of VICAM. "The expanded resources and increased opportunities we will gain at the Milford site promise to enhance our current product line and leadership in food testing and fuel the growth of our product line in additional directions," he added.
VICAM portfolio of single-use safety tests is designed to meet the increasingly more stringent regulatory and economic challenges. With the ultra-sensitivity to detect mycotoxins and other micro contaminants in parts per billion and its proven reliability across diverse formats, VICAM monoclonal antibody technology along with its specialized distributor commitment to fair pricing and strong customer service continues to sustain the company's market dominance in over 100 countries worldwide.
From rapid screening with test strips and IA columns coupled with fluorometry or advanced laboratory analysis by HPLC, Ultra Performance LCÂ (UPLCÂ) and mass spectrometry (MS), our product line is the industry standard in regulatory-compliant mycotoxin testing, said Radlo.
With this recognized strength in mycotoxin test methods linked to Waters powerhouse capabilities in separations and detection. VICAM, a Waters Business, is ideally positioned for the increasingly demanding 21st century marketplace, he added.
Waters Corporation with its portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, its technology breakthroughs and laboratory solutions provide an enduring platform for customer success.
With revenue of $1.58 billion in 2008 and 5,000 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.
Since 1985, VICAM has been dedicated to developing US FDA- and AOAC-approved rapid tests for mycotoxin. VICAM mycotoxin test kits offer a choice of rapid qualitative screening and quantitative test methods for a wide variety of mycotoxins.